Exploring the Cause of Oseltamivir Resistance Against Mutant H274Y Neuraminidase by Molecular Simulation Approach

Oseltamivir (Tamiflu) is the preferred anti-viral drug employed to fight the flu virus in infected individuals. The principal target for this drug is a virus surface glycoprotein, neuraminidase (NA), which facilitates the release of nascent virus and thus spreads infections. Until recently, only a low prevalence of neuraminidase inhibitors (NAIs) resistance (<1 %) had been detected in circulating viruses. However, there have been reports of significant numbers of A (H1N1) influenza strains with a H274Y neuraminidase mutation that was highly resistant to the NAI, oseltamivir. In this study, we highlight the effect of point mutation-induced oseltamivir resistance in H1N1 subtype neuraminidases by molecular docking and molecular dynamics simulation approach. Our results suggested that wild-type NA could be more indispensable for the oseltamivir binding, as characterized by minimum number of H-bonds, high flexibility and largest binding affinity than mutant-type NA. This study throws light on the possible effects of drug-resistant mutations on the large functionally important collective motions in biological systems.

[1]  Charles J. Russell,et al.  Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[3]  L. Gubareva,et al.  Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. , 2004, Virus research.

[4]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[5]  Alan J. Hay,et al.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.

[6]  R. Purohit,et al.  Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach. , 2008, Comptes rendus biologies.

[7]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[8]  L. Tobacman,et al.  Folding and Function of the Troponin Tail Domain , 2003, The Journal of Biological Chemistry.

[9]  K. Chou,et al.  Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. , 2007, Biochemical and biophysical research communications.

[10]  Jianguo Wu,et al.  Origin of highly pathogenic H5N1 avian influenza virus in China and genetic characterization of donor and recipient viruses. , 2007, The Journal of general virology.

[11]  J A McCammon,et al.  Accommodating protein flexibility in computational drug design. , 2000, Molecular pharmacology.

[12]  John E. Johnson,et al.  Bacteriophage lambda stabilization by auxiliary protein gpD: timing, location, and mechanism of attachment determined by cryo-EM. , 2008, Structure.

[13]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[14]  S. Parthasarathy,et al.  Protein thermal stability: insights from atomic displacement parameters (B values). , 2000, Protein engineering.

[15]  K. A. Snyder,et al.  A complete small molecule dataset from the protein data bank , 2006, FEBS letters.

[16]  G Bricogne,et al.  The 1.2 A crystal structure of hirustasin reveals the intrinsic flexibility of a family of highly disulphide-bridged inhibitors. , 1999, Structure.

[17]  J. N. Varghese,et al.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.

[18]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[19]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[20]  E. D. Kilbourne,et al.  A2 (N2) Neuraminidase of the X-7 Influenza Virus Recombinant: Determination of Molecular Size and Subunit Composition of the Active Unit , 1972, Journal of virology.

[21]  H. Berendsen,et al.  ALGORITHMS FOR MACROMOLECULAR DYNAMICS AND CONSTRAINT DYNAMICS , 1977 .

[22]  T. Creighton.  Methods in Enzymology , 1968, The Yale Journal of Biology and Medicine.

[23]  T Darden,et al.  New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. , 1999, Structure.

[24]  Alfonso Valencia,et al.  firestar—prediction of functionally important residues using structural templates and alignment reliability , 2007, Nucleic Acids Res..

[25]  J. McKimm-Breschkin,et al.  Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.

[26]  Karsten Suhre,et al.  ElNémo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement , 2004, Nucleic Acids Res..

[27]  S. Teague.  Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.

[28]  Thanyada Rungrotmongkol,et al.  How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? , 2009, Biophysical chemistry.

[29]  B. X. Carlson,et al.  A single glycine residue at the entrance to the first membrane-spanning domain of the gamma-aminobutyric acid type A receptor beta(2) subunit affects allosteric sensitivity to GABA and anesthetics. , 2000, Molecular pharmacology.

[30]  Claudio N. Cavasotto,et al.  Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.

[31]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[32]  Dagmar Ringe,et al.  [19]Study of protein dynamics by X-ray diffraction , 1986 .

[33]  W G Laver,et al.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.

[34]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[35]  Zheng Yuan,et al.  Prediction of protein B‐factor profiles , 2005, Proteins.

[36]  H. Carlson,et al.  Solvation influences flap collapse in HIV‐1 protease , 2004, Proteins.